Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia
Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Chronic myeloid leukemia (CML) is a clonal stem-cell disorder in which the reciprocal translocation t(9;22) generates two novel fusion genes:
BCR-ABL
on the derivative 22q– (Philadelphia) chromosome, and
ABL-BCR
on chromosome 9q+. The
ABL
gene product is a protein tyrosine kinase, and the fusion protein BCR-ABL has constitutive ki...
Alternative Titles
Full title
Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_73093793
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_73093793
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMe030009
